company background image
ICUI

ICU MedicalNasdaqGS:ICUI Stock Report

Last Price

US$208.69

Market Cap

US$5.0b

7D

-1.6%

1Y

2.6%

Updated

26 Jan, 2022

Data

Company Financials +
ICUI fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance4/6
Financial Health6/6
Dividends0/6

ICUI Stock Overview

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide.

ICU Medical Competitors

Abbott Laboratories

NYSE:ABT

US$211.4b

Medtronic

NYSE:MDT

US$140.1b

Siemens

XTRA:SIE

€111.1b

Becton Dickinson

NYSE:BDX

US$73.6b

Price History & Performance

Summary of all time highs, changes and price drops for ICU Medical
Historical stock prices
Current Share PriceUS$208.69
52 Week HighUS$282.00
52 Week LowUS$183.39
Beta0.51
1 Month Change-12.72%
3 Month Change-9.36%
1 Year Change2.62%
3 Year Change-13.15%
5 Year Change52.50%
Change since IPO4,425.81%

Recent News & Updates

Dec 05
Is Now The Time To Put ICU Medical (NASDAQ:ICUI) On Your Watchlist?

Is Now The Time To Put ICU Medical (NASDAQ:ICUI) On Your Watchlist?

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

Shareholder Returns

ICUIUS Medical EquipmentUS Market
7D-1.6%-4.3%-5.1%
1Y2.6%-3.7%3.3%

Return vs Industry: ICUI exceeded the US Medical Equipment industry which returned -3.7% over the past year.

Return vs Market: ICUI matched the US Market which returned 3.3% over the past year.

Price Volatility

Is ICUI's price volatile compared to industry and market?
ICUI volatility
ICUI Average Weekly Movement3.1%
Medical Equipment Industry Average Movement8.5%
Market Average Movement6.7%
10% most volatile stocks in US Market15.4%
10% least volatile stocks in US Market2.4%

Stable Share Price: ICUI is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: ICUI's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19847,900Vivek Jainhttps://www.icumed.com

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company’s infusion therapy products include needlefree connector products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoLock and ChemoClave closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, including sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation, such as sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options.

ICU Medical Fundamentals Summary

How do ICU Medical's earnings and revenue compare to its market cap?
ICUI fundamental statistics
Market CapUS$4.95b
Earnings (TTM)US$109.35m
Revenue (TTM)US$1.30b

45.3x

P/E Ratio

3.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ICUI income statement (TTM)
RevenueUS$1.30b
Cost of RevenueUS$812.36m
Gross ProfitUS$483.87m
ExpensesUS$374.52m
EarningsUS$109.35m

Valuation

Is ICU Medical undervalued compared to its fair value and its price relative to the market?

10.1%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ICUI ($208.69) is trading below our estimate of fair value ($232.03)

Significantly Below Fair Value: ICUI is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: ICUI is poor value based on its PE Ratio (45.3x) compared to the US Medical Equipment industry average (45.1x).

PE vs Market: ICUI is poor value based on its PE Ratio (45.3x) compared to the US market (16.4x).


Price to Earnings Growth Ratio

PEG Ratio: ICUI is poor value based on its PEG Ratio (4.3x)


Price to Book Ratio

PB vs Industry: ICUI is good value based on its PB Ratio (3.1x) compared to the US Medical Equipment industry average (3.3x).


Future Growth

How is ICU Medical forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

10.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ICUI's forecast earnings growth (10.7% per year) is above the savings rate (2%).

Earnings vs Market: ICUI's earnings (10.7% per year) are forecast to grow slower than the US market (12.9% per year).

High Growth Earnings: ICUI's earnings are forecast to grow, but not significantly.

Revenue vs Market: ICUI's revenue (18.3% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: ICUI's revenue (18.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ICUI's Return on Equity is forecast to be low in 3 years time (7%).


Past Performance

How has ICU Medical performed over the past 5 years?

13.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ICUI has high quality earnings.

Growing Profit Margin: ICUI's current net profit margins (8.4%) are higher than last year (6.4%).


Past Earnings Growth Analysis

Earnings Trend: ICUI's earnings have grown by 13% per year over the past 5 years.

Accelerating Growth: ICUI's earnings growth over the past year (34.4%) exceeds its 5-year average (13% per year).

Earnings vs Industry: ICUI earnings growth over the past year (34.4%) underperformed the Medical Equipment industry 51.2%.


Return on Equity

High ROE: ICUI's Return on Equity (6.9%) is considered low.


Financial Health

How is ICU Medical's financial position?


Financial Position Analysis

Short Term Liabilities: ICUI's short term assets ($1.0B) exceed its short term liabilities ($185.1M).

Long Term Liabilities: ICUI's short term assets ($1.0B) exceed its long term liabilities ($64.3M).


Debt to Equity History and Analysis

Debt Level: ICUI is debt free.

Reducing Debt: ICUI had no debt 5 years ago.

Debt Coverage: ICUI has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ICUI has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is ICU Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ICUI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ICUI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ICUI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ICUI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ICUI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Vivek Jain (49 yo)

7.92yrs

Tenure

US$3,312,999

Compensation

Mr. Vivek Jain has been an Independent Director of Envista Holdings Corporation since April 7, 2020. Mr. Jain has been Chairman and Chief Executive Officer of ICU Medical, Inc. since February 13, 2014. Mr....


CEO Compensation Analysis

Compensation vs Market: Vivek's total compensation ($USD3.31M) is below average for companies of similar size in the US market ($USD6.49M).

Compensation vs Earnings: Vivek's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ICUI's management team is considered experienced (4 years average tenure).


Board Members

Experienced Board: ICUI's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.1%.


Top Shareholders

Company Information

ICU Medical, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: ICU Medical, Inc.
  • Ticker: ICUI
  • Exchange: NasdaqGS
  • Founded: 1984
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: US$4.954b
  • Shares outstanding: 23.74m
  • Website: https://www.icumed.com

Number of Employees


Location

  • ICU Medical, Inc.
  • 951 Calle Amanecer
  • San Clemente
  • California
  • 92673
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/26 23:57
End of Day Share Price2022/01/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.